How much does an insulin pump cost in Australia?

When researching diabetes technology, one of the most common questions is about affordability. How much does an insulin pump cost? The total expense can vary significantly depending on the type of pump, features, and how you access it. In general, this may include: 

  • The initial device or system cost 
  • Ongoing consumables (such as infusion sets or Pods) 
  • Optional continuous glucose monitoring (CGM) integration 

Some people access them through private health insurance, while others may be eligible for government subsidies, which can help reduce overall costs.

 

How can I access an insulin pump? 

To access a pump, you will need to discuss your eligibility with your diabetes healthcare team. Once you’ve consulted with your team and decided to move forward, they will support you by preparing all required documentation, including order forms, letters of support, and any necessary private health forms.

 

NDSS subsidy: what support is available? 

The National Diabetes Services Scheme (NDSS) is an Australian Government program that helps people with diabetes access subsidised products and support services, including insulin pump consumables.

 

What does the NDSS cover? 

For eligible individuals, the NDSS provides partial subsidies on insulin pump consumables, which may include: 

  • Infusion sets and reservoirs for traditional pumps 
  • Wearable Pods for tubeless systems 

These consumables represent an ongoing cost, so NDSS support can help reduce the long-term insulin pump cost. 

 

Who is eligible? 

To access NDSS-subsidised insulin pump consumables, you must: 

  • Be living with type 1 diabetes 
  • Be registered with the NDSS 
  • Have an Insulin Pump Consumable Access Form completed and certified by a diabetes healthcare professional 

 

How to access NDSS-subsidised consumables 

Access typically involves: 

  • Consulting your diabetes healthcare team 
  • Completing the Insulin Pump Consumable Access Form 
  • Submitting the form to the NDSS 
  • Once approved, collecting consumables from an NDSS Access Point (usually a community pharmacy) 

 

How NDSS affects overall insulin pump cost 

The total expense will depend on how you access your system: 

  • With private health insurance: Your policy may cover the upfront cost of the pump, while consumables are subsidised through the NDSS. 
  • Without private health insurance: Some systems may be accessed via ongoing payment models, with NDSS subsidies helping reduce consumable costs. 

Even with subsidies, a co-payment applies when collecting consumables through the NDSS, and usage limits may apply depending on the product. 

 

The Omnipod® 5 difference: no lock-in subscription and pay-as-you go 

In Australia, the Omnipod® 5 Automated Insulin Delivery (AID) System is currently the only tubeless insulin pump available and uses a different pricing model compared to other pumps. 

Rather than requiring a large upfront cost, Omnipod 5 is designed as a pay-as-you-go system, where you purchase wearable Pods that are replaced every few days. 

Costs typically include: 

  • An initial starter kit to begin using the system 
  • Ongoing Pod purchases (each Pod is worn for up to 3 days/72 hours) 
  • Optional continuous glucose monitoring (CGM) sensors, which are sold separately 

Explore the cost of Omnipod® 5 in Australia

Get a clear breakdown of pricing, access pathways, and ongoing costs to see if Omnipod 5 is right for you.

Podder, sitting at the table with a book and crayons, and a plate of eaten oranges Podder, sitting at the table with a book and crayons, and a plate of eaten oranges
Jessica Sparks Lilley (pediatric endocrinologist)

Article by

Jessica Sparks Lilley (pediatric endocrinologist)

Last updated 25/03/26

Jessica Sparks Lilley is a pediatric endocrinologist and the senior manager of field medical affairs at Insulet Corporation. She was drawn to her career field by beloved family members who were diagnosed in early childhood with T1DM. She trained at Vanderbilt Children’s Hospital and the Children’s Hospital of Philadelphia. Her passion for her home state drew her to practice in rural Mississippi for 13 years, first building an academic satellite clinic then a new multispecialty clinic with far-flung outreach, each from the ground up. She had a regular column in Medscape, “It’s a Small World,” on a variety of topics in pediatric endocrinology. Her research focused on diabetes numeracy and inherited lipid disorders. She has actively supported Breakthrough T1D and the Diabetes Foundation of Mississippi. She is passionate about expanding access of diabetes technology to people living with diabetes and joined Insulet in 2024 after seeing the transformative impact of automated insulin delivery in her patients and loved ones.

Related Articles

How Can I get an Insulin Pump in Australia?

Diabetes tech discussion guide: Access and next steps with your care team


 

​​​Insulin Pumps, Explained

Are you thinking about using an insulin pump to manage your diabetes?  There’s a lot to consider, and terms like ‘patch pump’ and ‘closed-loop’ might be new to you. Let’s find out what an insulin…

What Is Insulin Pod Therapy?

Discover the advantages of Insulin Pod Therapy with Omnipod®. Learn how this tubeless insulin pump can enhance your diabetes management by offering the same benefits as traditional pump therapy, but with more freedom and…

Other topics

References and Disclaimers

1Insulin pump use in Australia (full publication; 8 Aug 2012 edition) (AIHW) 

The Omnipod 5 Automated Insulin Delivery System is a single hormone insulin delivery system intended to deliver U-100 insulin subcutaneously for the management of type 1 diabetes in persons aged 2 and older requiring insulin. The Omnipod 5 System is intended to operate as an automated insulin delivery system when used with compatible Continuous Glucose Monitors (CGM). When in automated mode, the Omnipod 5 system is designed to assist people with type 1 diabetes in achieving glycaemic targets set by their healthcare providers. It is intended to modulate (increase, decrease or pause) insulin delivery to operate within predefined threshold values using current and predicted CGM values to maintain blood glucose at variable target glucose levels, thereby reducing glucose variability. This reduction in variability is intended to lead to a reduction in the frequency, severity, and duration of both hyperglycaemia and hypoglycaemia. The Omnipod 5 System can also operate in a manual mode that delivers insulin at set or manually adjusted rates. 

The Omnipod 5 System is intended for single patient use. The Omnipod 5 System is indicated for use with NovoLog®/NovoRapid®, Humalog® / Liprolog®, Admelog® / Insulin lispro Sanofi®, Trurapi® / Insulin aspart Sanofi®, and Kirsty® U-100 insulin. Warning: SmartAdjust™ technology should NOT be used by anyone under the age of 2 years old. SmartAdjust™ technology should also NOT be used in people who require less than 5 units of insulin per day as the safety of the technology has not been evaluated in this population. The Omnipod® 5 System is NOT recommended for people who are unable to monitor glucose as recommended by their healthcare provider, are unable to maintain contact with their healthcare provider, are unable to use the Omnipod® 5 System according to instructions, are taking hydroxyurea and using a Dexcom Sensor as it could lead to falsely elevated CGM values and result in over-delivery of insulin that can lead to severe hypoglycaemia, and do NOT have adequate hearing and/or vision to allow recognition of all functions of the Omnipod® 5 System, including alerts, alarms, and reminders. Device components including the Pod, CGM transmitter, and CGM sensor must be removed before Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scan, or diathermy treatment. In addition, the Controller and smartphone should be placed outside of the procedure room. Exposure to MRI, CT, or diathermy treatment can damage the components. 

Warning: DO NOT start to use the Omnipod® 5 System or change settings without adequate training and guidance from a healthcare provider. Initiating and adjusting settings incorrectly can result in over-delivery or under-delivery of insulin, which could lead to hypoglycaemia or hyperglycaemia.